November 2023 updates to the website

The website has now been updated following November's LSCMMG

The following guidelines have been added/updated:

Lipid management pathway - Update to follow

The following medicines have been updated following the Commissioning Resource Group (CRG) meeting:

Bempedoic acid (without ezetimibe) - Treatment of primary hypercholesterolaemia or mixed dyslipidaemia

Tamoxifen - For treating premenopausal women at high risk of breast cancer unless they have a past history or may be at increased risk of thromboembolic disease or endometrial cancer.

Omega 3-acid-ethyl esters - For preterm birth risk reduction

Tacrolimus - For prophylaxis of graft rejection

The following Items will be updated and added to the website following the next Commissioning Resource Group (CRG) Meeting:

Ranolazine - As adjunctive therapy in the treatment of stable angina in patients inadequately controlled or intolerant of first-line antianginal therapies

Bimekizumab - active psoriatic arthritis (NICE TA916)

Bimekizumab - axial spondyloarthritis (NICE TA918)

Rimegepant - treating migraine (NICE TA919)

Tofacitinib - active ankylosing spondylitis (NICE TA920)

Mirikizumab - moderately to severely active ulcerative colitis (NICE TA925)

Baricitinib - severe alopecia areata (NICE TA926)